USPTO serial 79302549
BILIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 6, 2022
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BILIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndrome, lupus, and multiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosis, namely, for use as ultrasound and x-ray contrast reagents; antibiotics; anti-inflammatory preparations; anti-cancer preparations; biological preparations for the treatment of cancer; cardiovascular pharmaceutical preparations; dermatological pharmaceutical products; diagnostic preparations for medical or veterinary purposes; genetic identity tests comprised of reagents for medical purposes; human vaccine preparations; medicines for dental purposes; medicines for intestinal disorders; ophthalmic preparations; pharmaceutical agents affecting digestive organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting sensory organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals for the treatment of erectile dysfunction; preparations for the treatment of asthma; tumor suppressing agents; vaccines; immunoassay reagents for medical use | ACTIVE | — |
| 042 | Pharmaceutical research services; drug discovery services; medical research; pharmaceutical product evaluation; scientific investigations for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; consulting on the testing, inspection and research of medical products for quality control purposes; providing information on the testing, inspection and research of medical products for quality control purposes; industrial research in the fields of medicine, health and pharmacology; engineering services in the medical technology field | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 3, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 9, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 9, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 6, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 6, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 6, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 11, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 5, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 22, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 22, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 21, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 21, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 8, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 8, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 1, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 13, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 28, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 28, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 28, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 28, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 31, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2022 | ALIE | ASSIGNED TO LIE | — |
| Mar 29, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 29, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 29, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 29, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 30, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 30, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 30, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 17, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 26, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 26, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 23, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 22, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 21, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 22, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 21, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |